Literature DB >> 16280338

Diabetes and schizophrenia 2005: are we any closer to understanding the link?

Richard I G Holt1, Chris Bushe, Leslie Citrome.   

Abstract

The association between schizophrenia and diabetes has been recognized for well over a century, but the underlying reasons for this association are unclear. In October 2003, an international group of diabetologists and psychiatrists met to review the literature relating to the association, and to create pragmatic guidelines for the management of diabetic risk in patients with severe mental illness. Since that meeting, over 100 additional papers have been published on the association between glucose abnormalities and schizophrenia, and this is a clear reflection of the level of interest in this clinically important area. Diabetes is highly prevalent among the schizophrenia population, but most sufferers remain undiagnosed in the community. The reasons why individuals with schizophrenia are more prone to developing diabetes than the general population are poorly defined, but likely to be multifactorial. The role of antipsychotic medications in the development of diabetes and other pre-diabetic states remains controversial, but it appears that the attributable risk is low. Traditional risk factors most probably account for much of the diabetes seen in schizophrenia populations, suggesting that routine screening and aggressive risk factor management are especially important in this patient group.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280338     DOI: 10.1177/0269881105058379

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  22 in total

1.  A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis.

Authors:  Christine L McKibbin; Shahrokh Golshan; Kathryn Griver; Katherine Kitchen; Thomas L Wykes
Journal:  Schizophr Res       Date:  2010-08       Impact factor: 4.939

Review 2.  Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.

Authors:  R I G Holt; R C Peveler
Journal:  Diabetologia       Date:  2006-05-13       Impact factor: 10.122

Review 3.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

4.  Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus.

Authors:  Chi-Shin Wu; Susan Shur-Fen Gau
Journal:  Schizophr Bull       Date:  2015-12-31       Impact factor: 9.306

Review 5.  Diabetes mellitus and severe mental illness: mechanisms and clinical implications.

Authors:  Richard I G Holt; Alex J Mitchell
Journal:  Nat Rev Endocrinol       Date:  2014-12-02       Impact factor: 43.330

6.  SNAP25 mutation disrupts metabolic homeostasis, steroid hormone production and central neurobehavior.

Authors:  Xiao Hao; Bing Zhu; Pinglin Yang; Dachuan Dong; Peyman Sahbaie; Peter L Oliver; Wen-Jun Shen; Salman Azhar; Fredric B Kraemer
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-11-24       Impact factor: 5.187

7.  The risk of diabetes in deficit schizophrenia.

Authors:  William R Keller; Carol Vidal; Eric S Park; Gregory P Strauss; Bernard A Fischer
Journal:  Clin Schizophr Relat Psychoses       Date:  2014-01

Review 8.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

9.  Genetic Determinants of Clozapine-Induced Metabolic Side Effects.

Authors:  Kamini Vasudev; Yun-Hee Choi; Ross Norman; Richard B Kim; Ute I Schwarz
Journal:  Can J Psychiatry       Date:  2016-09-29       Impact factor: 4.356

10.  Physical complications in early clozapine treatment: a case report and implications for safe monitoring.

Authors:  Sachin S Patel; Matthew P G Allin
Journal:  Ther Adv Psychopharmacol       Date:  2011-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.